Addressing the commercial determinants of health begins with clearer definition and measurement

Benziger C Roth G Moran A. The global burden of disease study and the preventable burden of NCD. Glob Heart. 2016; 11: 393–397.

World Health Organization (WHO). Noncommunicable diseases. Fact Sheets [Internet]. Geneva: WHO; 1 June 2018 [cited 2020 April 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.

World Health Organization (WHO). Noncommunicable Diseases Progress Monitor. Geneva: WHO; 2015.

European Commission. Cost of non-communicable diseases in the EU [Internet]. Health Promotion and Disease Prevention Knowledge Gateway. 2019 [cited 2020 April 29]. Available from: https://ec.europa.eu/jrc/en/health-knowledge-gateway/societal-impacts/costs.

Wild S Roglic G Green A Sicree R King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care [Internet]. 2004 [cited 2020 April 29]; 27(5): 1047–1053. Available from: https://www.who.int/diabetes/facts/en/diabcare0504.pdf.

International Diabetes Federation. Diabetes Atlas, 9th edition [Internet]. 2019 [cited 2020 April 29]. Available from: https://diabetesatlas.org/.

Bollyky T Templin T Cohen M Deileman J. Lower-income countries that face the most rapid shift in noncommunicable disease burden are also the least prepared. Health Aff [Internet]. 2017 [cited 2020 April 28]; 36(11). Available from: https://www.healthaffairs.org/doi/10.1377/hlthaff.2017.0708.

Di Cesare M Khang YH Asaria P Blakely T Cowan MJ Farzadfar F , et al. Inequalities in non-communicable diseases and effective responses. Lancet. 2013; 381: 585–597.

Buse K Tanaka S Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Global Health. 2017; 13: 34.

Bertram M Sweeney K Lauer J Chisholm D Sheehan P Rasmussen B , et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018; 391: 2071–2079.

World Health Organization (WHO). Risk factors [Internet]. Geneva: WHO; n.d. [cited 2020 April 29]. Available from: https://www.who.int/topics/risk_factors/en/

WHO Independent High-Level Commission on NCDs. Think piece: why is 2018 a strategically important year for NCDs? Geneva: WHO; 2018 [cited 2020 April 29]. Available from: https://www.who.int/ncds/governance/high-level-commission/why-2018-important-year-for-NCDs.pdf.

Horton R. Comment: NCDs – why are we failing? Lancet [Internet]. 2017 [cited 2020 April 29]; 390: 346. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31919-0/fulltext.

Marley T Metzger M. A longitudinal study of structural risk factors for obesity and diabetes among American Indian young adults, 1994-2008. Prev Chronic Dis. 2015; 12: 140469.

Buse K Lee K. Business and global health governance. Discussion Paper No. 5. Geneva: WHO and LSHTM; 2005.

Lee K Smith J. The role of business in global health politics. In: McInnes C Lee K Youde J (eds). Oxford Handbook of Global Health Politics. Oxford: Oxford University Press; 2020: 387–408.

Mercer AJ. Updating the epidemiological transition model. Epidemiol Infect [Internet]. 2018 [cited 2020 April 28]; 146(6): 680–687. Available from: https://www.cambridge.org/core/journals/epidemiology-and-infection/article/updating-the-epidemiological-transition-model/D7933473050AC3A093C10DF34B779492/core-reader.

Freudenberg N . The manufacture of lifestyle: the role of corporations in unhealthy living. J Public Health Policy 2012; 33: 1–13.

West R Marteau T . Commentary on Casswell (2013): the commercial determinants of health. Addiction. 2013; 108: 686–687.

Kickbusch I Allen I Franz C. The commercial determinants of health. Lancet Glob Health. 2016; 4: e895–e896.

Buse K Tanaka S Hawkes S. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Health. 2017; 13: 34.

World Health Organization (WHO). Framework of engagement with non-State actors (FENSA). Sixty-Ninth World Health Assembly; May 28, 2016. WHA69/10.1.

World Health Organization (WHO). Time to deliver: report of the high-level commission on non-communicable diseases. Geneva: WHO; 2018 [cited 2020 April 29]. Available from: https://apps.who.int/iris/bitstream/handle/10665/272710/9789241514163-eng.pdf?ua=1.

Williams G. The determinants of health: structure, context and agency. Sociol Health Illn [Internet]. 2003 [cited 2020 April 29]; 25: 131–154. Available from: https://onlinelibrary.wiley.com/doi/pdf/10.1111/1467-9566.00344.

Milsom P Smith R Walls H. A systems thinking approach to inform coherent policy action for NCD Prevention; Comment on ‘How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention’. Int J Health Policy Manag [Internet]. 2020 [cited 2020 April 29]. Available from: http://www.ijhpm.com/article_3700.html.

Smith J. Towards critical analysis of the political determinants of health; Comment on ‘How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD Prevention’. Int J Health Policy Manag. 2020; 9: 121–123.

Freudenberg N. Defining appropriate roles for corporations in public health research and practice. Am J Public Health. 2018; 108: 1440–1441.